These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9840525)

  • 1. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
    Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
    Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific membrane antigen: current and future utility.
    Gregorakis AK; Holmes EH; Murphy GP
    Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
    Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
    Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
    Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
    Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
    Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific membrane antigen (PSMA): current benefits and future value.
    Elgamal AA; Holmes EH; Su SL; Tino WT; Simmons SJ; Peterson M; Greene TG; Boynton AL; Murphy GP
    Semin Surg Oncol; 2000; 18(1):10-6. PubMed ID: 10617892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical role of prostate-specific membrane antigen (PSMA).
    Chang SS; Heston WD
    Urol Oncol; 2002; 7(1):7-12. PubMed ID: 12474535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
    Chang SS; Reuter VE; Heston WD; Gaudin PB
    Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
    Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD
    Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
    Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
    Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
    Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
    Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA specific antibodies and their diagnostic and therapeutic use.
    Holmes EH
    Expert Opin Investig Drugs; 2001 Mar; 10(3):511-9. PubMed ID: 11227049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.
    Xiao Z; Adam BL; Cazares LH; Clements MA; Davis JW; Schellhammer PF; Dalmasso EA; Wright GL
    Cancer Res; 2001 Aug; 61(16):6029-33. PubMed ID: 11507047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
    Frigerio B; Fracasso G; Luison E; Cingarlini S; Mortarino M; Coliva A; Seregni E; Bombardieri E; Zuccolotto G; Rosato A; Colombatti M; Canevari S; Figini M
    Eur J Cancer; 2013 Jun; 49(9):2223-32. PubMed ID: 23433847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
    Ross JS; Sheehan CE; Fisher HA; Kaufman RP; Kaur P; Gray K; Webb I; Gray GS; Mosher R; Kallakury BV
    Clin Cancer Res; 2003 Dec; 9(17):6357-62. PubMed ID: 14695135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?
    Tasch J; Gong M; Sadelain M; Heston WD
    Crit Rev Immunol; 2001; 21(1-3):249-61. PubMed ID: 11642607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.